Results 81 to 90 of about 10,751 (182)

Ramucirumab in patients with advanced gastric and gastroesophageal junction cancer: Learnings from East Asian data

Journal of Cancer Research and Practice, 2018
Advanced gastric and gastroesophageal junction cancers remain a major cause of concern considering their high incidence in Taiwan, poor outcomes essentially due to diagnosis at the advanced stage, and poor prognosis.
Chia-Jui Yen, Li-Yuan Bai, Rebecca Cheng, Frank Hsiao, Mauro Orlando   +4 more
doaj   +1 more source

Liver Metastases from Colorectal Cancer: From Pathogenesis to Current Treatment

MedComm, Volume 7, Issue 10, October 2026.
The liver is not merely a passive recipient of disseminated tumor cells, but a unique metastatic organ shaped by anatomical, metabolic, and immunological characteristics that support tumor colonization. Increasing evidence indicates that colorectal cancer liver metastasis development is driven by dynamic interactions between tumor intrinsic programs ...
Jialiang Fan, Huiru Zhang, Deyang Kong, Yu Sun, Shuaibing Lu, Wenjing Yang, Renshen Xiang, Qi Zhang, Wei Pei, Haizeng Zhang, Lin Feng   +10 more
wiley   +1 more source

Is ramucirumab and paclitaxel therapy beneficial for second-line treatment of metastatic gastric or junctional adenocarcinoma for patients with ascites? Analysis of RAINBOW phase 3 trial data

, 2019
Kei Muro,1 Min-Hua Jen,2 Rebecca Cheng3 1Department of Clinical Oncology, Outpatient Treatment Center, Aichi Cancer Center Hospital, Nagoya, Japan; 2Eli Lilly and Company Ltd, Windlesham, Surrey, UK; 3Eli Lilly and Company, Taipei, Taiwan Purpose: Second-
Jen MH, Cheng R, Muro K
core  

Renal-limited thrombotic microangiopathy after switching from bevacizumab to ramucirumab: a case report

, 2019
Background It is well known that vascular endothelial growth factor (VEGF) inhibitors can cause proteinuria. The incidence of proteinuria is high for bevacizumab, a humanized monoclonal antibody directed against VEGF, but the range of proteinuria rarely ...
Ryo Yamada, Ken Matsuo, Kiyoshi Mori, Makoto Suzuki, Noriko Mori, Takao Okawa   +5 more
core   +1 more source

Assessing patient risk, benefit, and outcomes in drug development: A decade of ramucirumab clinical trials

Cancer Medicine
Objective This study aims to evaluate published clinical trials of ramucirumab to assess the risk/benefit profile and burden over time for patients. Background The burden of oncologic drug development on patients paired with increasing clinical trial ...
Adam Khan, Hassan Khan, Griffin K. Hughes, Chase Ladd, Ryan McIntire, Brooke Gardner, Andriana M. Peña, Abigail Schoutko, Jordan Tuia, Kirstien Minley, Alyson Haslam, Vinay Prasad, Matt Vassar   +12 more
doaj   +1 more source

Second-line treatment in advanced gastric cancer: Data from the Spanish AGAMENON registry.

PLoS ONE, 2020
BackgroundSecond-line treatments boost overall survival in advanced gastric cancer (AGC). However, there is a paucity of information as to patterns of use and the results achieved in actual clinical practice.Materials and methodsThe study population ...
Almudena Cotes Sanchís, Javier Gallego, Raquel Hernandez, Virginia Arrazubi, Ana Custodio, Juana María Cano, Gema Aguado, Ismael Macias, Carlos Lopez, Flora López, Laura Visa, Marcelo Garrido, Nieves Martínez Lago, Ana Fernández Montes, María Luisa Limón, Aitor Azkárate, Paola Pimentel, Pablo Reguera, Avinash Ramchandani, Juan Diego Cacho, Alfonso Martín Carnicero, Mónica Granja, Marta Martín Richard, Carolina Hernández Pérez, Alicia Hurtado, Olbia Serra, Elvira Buxo, Rosario Vidal Tocino, Paula Jimenez-Fonseca, Alberto Carmona-Bayonas   +29 more
doaj   +1 more source

Logistic regression analysis for pneumonitis associated with ramucirumab and paclitaxel combination treatment.

, 2018
Logistic regression analysis for pneumonitis associated with ramucirumab and paclitaxel combination treatment.
Sou Katayanagi (5349557), Shigeyuki Kawachi (5349554), Nobuyuki Koyama (2733205)   +2 more
core   +1 more source

Comparison of Tepotinib, Paclitaxel, or Ramucirumab Efficacy According to the Copy Number or Phosphorylation Status of the MET Gene: Doublet Treatment versus Single Agent Treatment

Although conventional combination chemotherapies for advanced gastric cancer (GC) increase survival, such therapies are associated with major adverse effects; more effective and less toxic treatments are required.
Dae Young Zang, Sung-Hwa Sohn, Bum Jun Kim, Hee Jung Sul   +3 more
core   +1 more source

Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): A randomised, double-blind, multicentre, phase 3 trial

, 2015
VEGF and VEGF receptor-2-mediated angiogenesis contribute to hepatocellular carcinoma pathogenesis. Ramucirumab is a recombinant IgG1 monoclonal antibody and VEGF receptor-2 antagonist.
Blanc JF, Park J. O., Craxì Antonio., Schwartz JD, Trojan J, Pfiffer T. E. F., Chau I., Pastorelli D., Okusaka T., Pastorelli D, Yang L., Baron AD, BRANDI, GIOVANNI, Zhu AX, Poon R., Zhu A. X., Sastre J., Ryoo BY, Baron A. D., Kudo M, Chau I, Chang SC, Ryoo B. -Y., Chang S. -C., Kudo M., Poon R, REACH Trial Investigators, Schwartz J. D., Yen CJ, Yang L, Yen C. -J., Trojan J., Chung HC, Okusaka T, Park JO, Abada P. B., Chung H. C., Blanc J. -F., Pfiffer TE, Abada PB, Kubackova K., Kubackova K, Sastre J   +42 more
core   +1 more source

Phase II study of ramucirumab and docetaxel for previously treated non‐small cell lung cancer patients with malignant pleural effusion: Protocol of PLEURAM study

Thoracic Cancer, 2020
Introduction Anti‐vascular endothelial growth factor therapy has been shown to be effective in non‐small cell lung cancer (NSCLC) patients with malignant pleural effusion (MPE); however, there are no data to suggest that ramucirumab has the same effects.
Shinnosuke Takemoto, Minoru Fukuda, Hiroyuki Yamaguchi, Takaya Ikeda, Kazumasa Akagi, Hiromi Tomono, Yasuhiro Umeyama, Yosuke Dotsu, Hirokazu Taniguchi, Hiroshi Gyotoku, Hiroaki Senju, Takeshi Kitazaki, Katsumi Nakatomi, Seiji Nagashima, Masaaki Fukuda, Akitoshi Kinoshita, Hiroshi Soda, Hiroshi Mukae   +17 more
doaj   +1 more source